Xuesong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xuesong Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Schulte-Mecklenbeck
Department of Neurology, University of Muenster, Germany; and
1 shared publication - Anna-Lena Börsch
Department of Neurology, Medical Faculty, University Hospital Münster, Münster, Germany
1 shared publication - Catharina C. Gross
Department of Neurology, University of Muenster, Germany; and
1 shared publication - Frederike Anne Straeten
Department of Neurology, Medical Faculty, University Hospital Münster, Münster, Germany
1 shared publication - Gerd Meyer zu Hörste
University Hospital Münster
1 shared publication - Heinz Wiendl
From the Department of Neurology and Neuroscience, Medical Center and Faculty of Medicine, University of Freiburg, Germany
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
A CSF disease-associated macrophage signature defines progressive multiple sclerosis
Objective: Progression in multiple sclerosis (MS) often corresponds to irreversible disability in MS patients. Cellular changes in the cerebrospinal fluid (CSF) have provided biomarkers and mechanisms in relapsing-remitting MS (RRMS) but remain understudied in primary and secondary progressive MS (summarized herein as PMS). Methods: We combined retrospective flow cytometry of CSF cells from RRMS ( n = 169), PMS ( n = 56), and non-inflammatory controls ( n = 74) with prospective CSF single-cell transcriptomics of 35 individuals (11 controls, 12 RRMS, and 12 PMS) and with confirmatory CSF ELISA. Available CSF single-cell data from age-matched and Alzheimer’s disease (AD) patients served as additional controls. Results: Proportions of CD14 + monocytes in CSF are increased in PMS and correlated with clinical surrogate markers of progression. Transcriptionally, these monocytes resembled border-associated macrophages (BAM)-like cells with a chronically activated antigen-presenting phenotype. Additionally, these monocytes shared some features with disease-associated microglia/macrophages (DAM), previously identified in neurodegeneration. Induction of DAM-associated molecules, including transcribed and soluble TREM2 (sTREM2), characterized secondary progressive MS (SPMS) and supported its differential diagnosis. Interpretation: We thus identified MS stage-specific CSF signatures and shared cellular features of degeneration detectable in CSF of PMS patients. Graphical
- 13 May 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessA CSF disease-associated macrophage signature defines progressive multiple sclerosis
Objective: Progression in multiple sclerosis (MS) often corresponds to irreversible disability in MS patients. Cellular changes in the cerebrospinal fluid (CSF) have provided biomarkers and mechanisms in relapsing-remitting MS (RRMS) but remain understudied in primary and secondary progressive MS (summarized herein as PMS). Methods: We combined retrospective flow cytometry of CSF cells from RRMS ( n = 169), PMS ( n = 56), and non-inflammatory controls ( n = 74) with prospective CSF single-cell transcriptomics of 35 individuals (11 controls, 12 RRMS, and 12 PMS) and with confirmatory CSF ELISA. Available CSF single-cell data from age-matched and Alzheimer’s disease (AD) patients served as additional controls. Results: Proportions of CD14 + monocytes in CSF are increased in PMS and correlated with clinical surrogate markers of progression. Transcriptionally, these monocytes resembled border-associated macrophages (BAM)-like cells with a chronically activated antigen-presenting phenotype. Additionally, these monocytes shared some features with disease-associated microglia/macrophages (DAM), previously identified in neurodegeneration. Induction of DAM-associated molecules, including transcribed and soluble TREM2 (sTREM2), characterized secondary progressive MS (SPMS) and supported its differential diagnosis. Interpretation: We thus identified MS stage-specific CSF signatures and shared cellular features of degeneration detectable in CSF of PMS patients. Graphical